In agreement, by a variety of approaches, regressive CIS lesions were shown to contain more lymphocytes, more intra-lesional CD8+ cells, and increased levels of genes coding for pro-inflammatory cytokines (IL2, TNF, IL12A, and IL23A) compared to CIS progressive lesions [21]. The gene discussed is IL23A; the disease is in situ carcinoma.